Which funds bought or sold DXCM in Q3 2026?
Dexcom Inc. 5 funds bought, 3 sold, out of 109 tracked funds that have filed for Q3 2026. Among active managers, the estimated net flow was −$1.1B.
Holdings as of Sep 30, 2026 (Q3 2026)13F deadline Nov 16, 2026 (45 days after quarter end)
- Citadel+$252M
- Renaissance+$62M
- ExodusPoint+$57M
- Legal & General+$17M
- PRIMECAP+$8M
- AllianceBernstein−$805M
- UBS−$307M
- Wellington−$288M
Top 10 each side. NEW = opened a position, OUT = sold the whole position.
Bought (5)
| Fund | Change | Est. $ | Now |
|---|---|---|---|
| Citadel Quant & multi-strategy | Added+241.3% | +$252M | $357M |
| Renaissance Quant & multi-strategy | Added+43.9% | +$62M | $202M |
| ExodusPoint Quant & multi-strategy | Added+567.5% | +$57M | $67M |
| Legal & General Asset manager | Added+7.7% | +$17M | $239M |
| PRIMECAP Growth / crossover | Added+50.2% | +$8M | $25M |
Sold (3)
| Fund | Change | Est. $ | Now |
|---|---|---|---|
| AllianceBernstein Asset manager | Trimmed-79.8% | −$805M | $204M |
| UBS Bank & broker | Trimmed-58.6% | −$307M | $217M |
| Wellington Asset manager | Trimmed-39.2% | −$288M | $447M |
Source: SEC EDGAR Form 13F-HR for each fund, holdings as of Sep 30, 2026. Shares only (options excluded). Estimated $ = change in shares × quarter-end price. Funds may have traded since. Methodology. Not investment advice.